Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Status:
Completed
Trial end date:
2019-06-07
Target enrollment:
Participant gender:
Summary
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir
followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic
hepatitis C (HCV) genotype 1 (GT1) infection
Phase:
Phase 2
Details
Lead Sponsor:
Cocrystal Pharma, Inc.
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination